China Adds Ascentage’s Lisaftoclax to 2026 Drug Reimbursement List
Lisaftoclax is newly covered and olverembatinib’s coverage was renewed, bringing all approved indications for both drugs onto the list.
Makkler Newsroom · Nov 16, 02:55 AM · 1 min read
